Kornimate/medical-research-clean huggingface dataset:
carbon ions radiation therapy for resectable or borderline resectable pancreas adenocarcinoma

Conditions: Cancer of Pancreas; Pancreas Adenocarcinoma; Resectable Pancreatic Cancer

Summary: relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.

enrolled subjects will undergo to 3 cycles of folfirinox before re-evaluation of the lesion. then, 4d planning and imaging with respiratory gating end rescanning technique will be adopted to calculate the optimal treatment plan to carbon ions radiation therapy: 38.4 gy\[rbe\] is the prescribed dose to ctv. 4.8 gy\[rbe\]/fraction will be delivered 4 times a week in two weeks. 4/6 weeks after hadrontherapy, after a ct scan with contrast, patient will undergo to a surgery. after 4/6 weeks, gemcitabine will be administered for 6 cycles. secondary endpoints of the trial are overall survival, resectability rate (operable vs borderline operable), acute toxicity within 3 months, 3-6 months, over 6 months.

Eligibility criteria:
inclusion criteria: * histologic/cytologic diagnosis of exocrine pancreas tumour * resectable or borderline resectable exocrine pancreatic tumour (according to operability criteria) * no metastasis from us, ct, pet, mri or laparotomy * karnofsky index \>= 70 * stomach and duodenum not infiltrated by tumour * given informed consent to study procedures * hb \> 9 g/dl, n\> 1500, plt\> 100000 * creatininemia \ 3 g/dl * dpd normal activity * contraception required and breast feeding not permitted exclusion criteria: * non resectable, locally advanced tumours * insular cells tumour * comorbidities excluding abdominal surgery and/or chemo- radiation therapy * known metastasis * dpd low activity * inability to attend study procedures and follow ups * pregnancy * previous diagnosis of other tumour with more disadvantageous prognosis then the study object * metallic biliary stent * metallic prothesis or any other condition to prevent from target volume individuation and dose calculation * clinical condition preventing from radiation therapy (i.e. infections in the irradiation area) * medical and/or psychical condition preventing from radiation therapy * past radiation therapy on abdomen.

Keywords: carbon ion radiation therapy exocrine pancreas pancreas tumour
identification of stroke at the emergency medical dispatch center

Conditions: Stroke

Summary: a study to investigate how stroke is identified and whether fast, face-arm-speech test, is used in the emergency medical dispatch centre in stockholm. the study will also investigate when fast is used, does it increase the identification of stroke? and if other factors can be identified as "markers" for more effective identification of stroke during the emergency call.

transcribed alarm calls are read through and analyzed using a qualitative method. meaningful units are identified, coded and categorized. a phenomenological analysis is also applied to a separate analysis.

Eligibility criteria:
inclusion criteria: * patients who has called the emergency medical dispatch centre and also are diagnosed as stroke at södersjukhuset during the study period. exclusion criteria: * cases where needed documents and files are missing.
the clinical effect of palliative treatment on patients with terminal cancer

Conditions: Multidisciplinary Collaborative; Palliative Care Model; Quality of Life

Summary: this study proposed a multidisciplinary collaborative team combined with a palliative care model and proposed to establish a team composed of medical staff in various disciplines to make up for the defects of a conventional nursing team. this study applied the multidisciplinary collaboration team combined with a palliative care model to patients with terminal cancer to evaluate its clinical effect.


Eligibility criteria:
inclusion criteria: * patients were diagnosed as terminal by imaging, pathology and clinical manifestations * the expected length of stay was more than seven days * patients with clear consciousness, good communication and understanding ability * voluntary participation in this study and signing of informed consent * the estimated survival period is more than three months exclusion criteria: * patients with cognitive impairment and mental illness * those who were seriously ill and could not cooperate with the completion * patients with severe communication disorders
new technique in congenital/pediatric cataract surgery

Conditions: Pediatric Cataract; Congenital Cataract

Summary: in pediatric/congenital cataract surgery; multiple surgical interventions are performed, which needs multiple general anesthesias. here, we describe a new technique, to end the operation in one session.

generally, in congenital/pediatric cataract surgery, it might be possible to different multiple procedures with multiple general anesthesias. here, the investigators found a new procedure to perform the cataract removal, intraocular implantation, and the anterior vitrectomy all in one session through a sclero-corneal tunnel. the corneoscleral tunnels are covered by the conjunctiva to abolish the need for both suturing and repeated general anesthesia to remove corneal sutures.

Eligibility criteria:
inclusion criteria: * congenital/pediatric cataract exclusion criteria: * aphakic and pseudophakic

Keywords: corneoscleral incision cataract surgery vitreorrhexis anterior vitrectomy
constitution of a prospective cohort of patients with acute suppurative hidrosadenitis followed in the great west: the cover cohort (verneuil cohort)

Conditions: Acute Hidrosadenitis

Summary: our primary objective with this cohort will be to define the different phenotypes of acute hidrosadenitis, the characterization of which is essential to define suitable therapeutic approaches. indeed, our recent data allow us to note that there would be different phenotypes of acute hidrosadenitis and therefore different pathologies inducing different follow-ups and care.


Eligibility criteria:
inclusion criteria: * patient diagnosed with acute hidrosadenitis by a dermatologist * patient agreeing to be part of the study exclusion criteria: * no affiliation to a social security scheme * major under guardianship * protected persons
longitudinal evaluation of gastric emptying and accommodation in children with dyspepsia

Conditions: Gastroparesis; Dyspepsia

Summary: the purpose of this research is to further study the relationship between gastroparesis (gp) (a condition in which the stomach cannot empty itself of food in a normal fashion) and functional dyspepsia (fd) (frequent symptoms of indigestion that have no obvious cause).


Eligibility criteria:
inclusion criteria: * able to complete the pediatric cardinal symptoms questionnaire * both parent and child must be able to speak and understand english or spanish exclusion criteria: * have global developmental delay, autism disorder, or psychosis * are nonverbal and/or illiterate * lack fluency in english or spanish * have other gi comorbidities such as inflammatory bowel disease, celiac disease, eosinophilic esophagitis, peptic ulcer disease, gi malignancy, or gastroesophageal reflux disease responsive to medications (medical records will be reviewed to detect these exclusions) * have a history of surgical procedures that could have potentially affected their gi tract anatomy, such as fundoplication or ladd's procedure. * healthy child presenting to their well child care visit must not report a history of dyspepsia, have a history of any gastrointestinal disease, or be taking any medication that can disturb the gi tract motility.
the effects of open chain versus closed chain strengthening on dynamic valgus during a step down test

Conditions: Dynamic Knee Valgus

Summary: the goal of this clinical trial is to compare the effects of different exercises programs in individuals with abnormal knee motion. the main question it aims to answer are: * in individuals with abnormal knee motion and without knee pain, does a weight-bearing exercise program reduce abnormal knee motion during a step-down test better than a non weight-bearing exercise program? participants will * perform a stepdown test while undergoing motion analysis and electromyograph (emg) recording. * participants will then be placed either into a weight-bearing or non weight-bearing exercise group. exercises will be performed 3 times per week for 6 weeks. * further motion analysis and emg data will be collected to test for differences. researchers will compare individual results before and after exercise, and between-group results before and after exercise to see if one exercise program helps improved abnormal knee motion more than the other.

the goals of this trial is to compare the effects of a closed kinetic chain exercise program to an open kinetic chain exercise program in individuals without knee pain who also have dynamic knee valgus during a step-down test. individuals will be screened for participation via visual observation. those with an observable medial collapse of the knee joint will then receive motion capture testing of the step down test (three trials) with electromyography recording of the gluteus medius, quadriceps and hamstring muscle groups. baseline maximum voluntary contraction of these muscles will be done with emg analysis and force gauge measurements. after initial data collection participants will be randomized into either a closed kinetic chain exercise group or open kinetic chain exercise group. (described in the arms section) participants will exercise 2-3 times per week for 6 weeks. after the exercise program is completed, participants will then be seen back for final data collection which will match the initial collection process.

Eligibility criteria:
inclusion criteria: * dynamic knee valgus with observed step down test exclusion criteria: * presently experiencing lower extremity pain * lower extremity surgery within the past 1 year

Keywords: knee valgus hip weakness
docetaxel or cabazitaxel with or without darolutamide in mcrpc

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: taxane efficacy in metastatic prostate cancer is modest due to resistance development. several clinical phase iii studies in metastatic castration-naïve prostate cancer (mcnpc) patients have shown that adding an androgen receptor signalling inhibitor (arsi) to patients receiving a taxane and androgen deprivation therapy (adt) improves survival endpoints. adding arsi darolutamide to docetaxel+adt in mcnpc patients resulted in a robust os benefit (hr 0.68). importantly, the combination of a taxane and darolutamide is not prone to a drug-drug interaction, while there is a detrimental cyp3a4 inducing effect in the case of enzalutamide, resulting in a significant and clinically relevant reduction of cabazitaxel plasma concentrations. the investigators have previously reported preclinical data showing that addition of an androgen receptor signaling inhibitor (arsi) improves cabazitaxel efficacy, even in metastatic castration-resistant prostate cancer (mcrpc). as treatment options for mcrpc) patients are scarce and patients often develop drug resistance relatively early, a new treatment regimen for this population to delay drug resistance is highly desired. the investigators propose a randomized phase ii trial to investigate the efficacy of docetaxel or cabazitaxel plus darolutamide compared to docetaxel or cabazitaxel monotherapy in men with metastatic crpc, who have progressed on an arsi.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. a confirmed diagnosis of progressive mcrpc (progression according to prostate cancer working group (pcwg) 3 criteria, castration defined as castrate levels of testosterone of \<0.5 ng/ml) with an indication for docetaxel or cabazitaxel. 3. patients should have had disease progression previously on at least one arsi (abiraterone, apalutamide, darolutamide or enzalutamide). arsi administration is allowed both in the mcnpc and in the mcrpc setting. previous co-administration of docetaxel in mcnpc (triplet-therapy) is allowed, if patients will receive cabazitaxel in this study. 4. who performance ≤ 2 5. able and willing to sign the informed consent form prior to screening evaluations 6. adequate haematological, renal and liver function and chemistry. exclusion criteria: 1. impossibility or unwillingness to take oral drugs 2. hypersensitivity to taxanes 3. known serious illness or medical unstable conditions that could interfere with this study requiring treatment (e.g. hiv, hepatitis, varicella zoster or herpes zoster, organ transplants, kidney failure, serious liver disease (e.g. severe cirrhosis), cardiac and respiratory diseases) 4. symptomatic peripheral neuropathy ctcae grade ≥2 5. docetaxel-rechallenge.
dose-exploration evaluating the efficacy and safety of voclosporin in subjects with focal segmental glomerulosclerosis

Conditions: Focal Segmental Glomerulosclerosis

Summary: evaluating the efficacy and safety of voclosporin in achieving complete or partial remission of proteinuria in subjects with focal segmental glomerulosclerosis

the aim of the current study to assess the efficacy of voclosporin in achieving complete or partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental glomerulosclerosis (fsgs). as well as to assess the safety and tolerability of voclosporin over 24 weeks in subjects with fsgs.

Eligibility criteria:
inclusion criteria: 1. primary fsgs diagnosed by renal biopsy. 2. urine protein creatinine ratio (upcr) ≥2.0 mg/mg, serum albumin ≤3.2 g/dl and can be immunosuppressant treatment-naïve, or receiving treatment with steroids. 3. stable proteinuria, renal function, and bp. exclusion criteria: 1. clinical or histologic evidence of secondary fsgs. 2. histologic evidence of collapsing variant fsgs. 3. egfr as calculated by the chronic kidney disease epidemiology collaboration (ckd-epi) equation of ≤30 ml/minute/1.73 m2 at initial screening assessment or ≤45 ml/minute/1.73 m2 at last qualifying assessment. 4. currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period. 5. current or medical history of: * congenital or acquired immunodeficiency. * in the opinion of the investigator, clinically significant drug or alcohol abuse within 2 years prior to screening. * malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision. * current or past lymphoproliferative disease or previous total lymphoid irradiation. * severe viral infection within 3 months of screening, or known hiv infection. severe viral infection is defined as active disease requiring antiviral therapy. * active tuberculosis (tb) or known history of tb/evidence of old tb if not taking prophylaxis with isoniazid.

Keywords: calcineurin inhibitors focal segmental glomerulosclerosis
a study of capecitabine rapid disintegrating tablets (rdt) versus commercial xeloda in patients with solid tumours

Conditions: Breast Cancer, Colorectal Cancer

Summary: this randomized, open-label, two-way crossover study will evaluate the relative bioavailabilty and safety of capecitabine rapid disintegrating tablets (rdt) versus commercial xeloda tablets in patients with colorectal or breast cancer. patients will be randomized to a sequence of single oral doses of capecitabine rdt or xeloda on days 1 and 2 of a 14-day treatment cycle with xeloda. follow-up will be 30 days.


Eligibility criteria:
inclusion criteria: * adult patients,\>/= 18 years of age * histological/cytological confirmation of colorectal or breast cancer * patient is ambulatory and has a karnofsky performance status of \> 70% * body surface area between 1.5 and 2.0 m2 * either: * due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or * currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2 exclusion criteria: * any contraindication to xeloda * received xeloda in the 6 days prior to day 1 * subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy) * renal impairment * pregnant or lactating females * participation in an investigational drug study within 28 days prior to screening * lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome * serious uncontrolled intercurrent infections * history of clinically significant coronary artery disease * concomitant treatment with warfarin * known dihydropyrimidine dehydrogenase deficiency
cis001 extension study of cyclosporine inhalation solution

Conditions: Lung Transplant

Summary: this trial is a longterm follow up of a phase iii study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.


Eligibility criteria:
inclusion criteria: 1. enrollment in study cis001 2. written informed consent for cis002 3. use of an effective means of contraception by women of childbearing potential exclusion criteria: 1. any unresolved or irreversible cis-related ongoing serious adverse event 2. subjects who have developed newly emergent conditions, injuries, diagnoses, physical examination findings, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk of treatment complications 3. subjects with suspected or documented allergy to propylene glycol and/or cyclosporine 4. women who are pregnant, wishing to become pregnant, or unwilling to use appropriate birth control to avoid becoming pregnant 5. women who are breastfeeding 6. subjects unable to comply with all protocol requirements and follow-up procedures 7. subjects who discontinued from cis002 to participate in another clinical trial and have received any investigational treatment (other than cis) within 14 days of titration visit 1/baseline.

Keywords: lung transplant lung transplant recipient bronchiolitis obliterans syndrome bronchiolitis obliterans single lung transplant double lung transplant heart-lung transplant aerosol
national lymphangioleiomyomatosis registry, france

Conditions: Lymphangioleiomyomatosis

Summary: re-lam-ce is a registry of lymphangioleiomyomatosis cases in france. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in france, including demographic information and information concerning the timing and modalities of diagnosis. based on the registry, we will set up a prospective cohort of patients. the database will include detailed medical information, particularly regarding progression of the respiratory function.

lymphangioleiomyomatosis is a rare pulmonary disease occuring preferentially in women. few data are available regarding the epidemiology of this disease, the frequency of the various forms with mild to moderate or severe disease, and the rapid or slow progression. several sources of information will be used in order to increase completeness. the registry will also allow to estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the reference center and competence centers for rare lung diseases in france. data will be collected by a research assistant, and the study will be coordinated by the pole imer - department of public health and epidemiology of hcl (lyon hospitals). this study will provide a better knowledge on the natural course of the disease and the variability in severity and progression of lymphangioleiomyomatosis, and the applicability of diagnostic criteria proposed in 2009. this study will provide the first detailed epidemiological information on lymphangioleiomyomatosis, will assess the management of this rare disease within the french national plan for rare diseases 2005 - 2009, and will provide valuable medical information prior to the establishment of clinical trials

Eligibility criteria:
inclusion criteria: * patients with sporadic lymphangioleiomyomatosis or associated with tuberous sclerosis. * patients diagnosed or hospitalized or seen in consultation since 01/01/2008 exclusion criteria: * none

Keywords: lymphangioleiomyomatosis
transversus thoracic muscle plane block, erector spinae plane block and paravertebral block for analgesia in video-assisted thoracic surgery

Conditions: Transversus Thoracic Muscle Plane Block; Erector Spinae Plane Block; Paravertebral Block; Analgesia; Video-Assisted Thoracic Surgery

Summary: the aim of this study is to compare the transversus thoracic muscle plane block (ttpb), erector spinae plane block (espb), and thoracic paravertebral block (tpvb) for postoperative analgesia in patients undergoing video-assisted thoracoscopic surgery (vats).

traditionally, resection is done via a thoracotomy. still, video-assisted thoracoscopic surgery (vats) provides significant advantages over open thoracotomy procedures, including reduced surgical pain, improved postoperative pulmonary function, reduced mortality, shortened hospital stay. it has emerged as a minimally invasive alternative. thoracic paravertebral block (tpvb) is a regional anesthetic technique in which local anesthetic (la) is administered inside the thoracic paravertebral space (tpvs), which contains the intercostal spinal nerves, spinal dorsal rami, rami communicants, sympathetic chain, intercostal vessels, and fatty tissue. the erector spinae plane block (espb) is an interfascial regional anesthesia block for thoracic analgesia which can be performed by superficial or deep needle approach. transversus thoracic muscle plane block (ttpb) is a newly developed technique in which la is injected into the fascial plane between the transversus thoracic muscle and the internal intercostal muscles for blocking the anterior cutaneous branches of intercostal nerves from thoracic (th) 2 to th 6.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * both sexes. * american society of anesthesiology (asa) physical status i-ii. * scheduled for video-assisted thoracic surgery under general anesthesia. exclusion criteria: * body mass index \>30 kg/m2. * coagulopathy. * history of opiate abuse. * pre-existing chronic pain. * allergy to local anesthetics or analgesics. * infection at the site of injection. * mental or neurological disorders. * operation converted to open thoracotomy. * renal dysfunction (glomerular filtration rate (gfr) \< 50 ml/min). * pregnancy